World Conference on Lung Cancer & ESMO Congress 2018 
Scientific Summaries 

Two of the most important conferences in non-small cell lung cancer (NSCLC) – the IASLC 19th World Conference on Lung Cancer (WCLC) and the ESMO Congress 2018 – are happening this fall. WCLC 2018 takes place September 23rd to 26th in Toronto, Canada, immediately followed by ESMO 2018 on October 19th to 23rd in Munich, Germany. M.D. /alert has compiled extensive coverage of the most important research, presentations, and breaking news unveiled at both WCLC 2018 and ESMO 2018, in order to keep clinicians up-to-date on the data that could change the standard of care for NSCLC.

 

 
Brigatinib Superior to Crizotinib for Frontline ALK+ NSCLC

Brigatinib Superior to Crizotinib for Frontline ALK+ NSCLC

First-line treatment with brigatinib appeared superior to crizotinib for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC)...
72% of NSCLC Patients with MET Mutation Respond to Capmatinib

72% of NSCLC Patients with MET Mutation Respond to Capmatinib

The Phase II GEOMETRY mono-1 study found that nearly three-quarters of treatment-naïve patients responded to capmatinib, a selective MET inhibitor...
ESMO 2018: Pembrolizumab Extends Quality Survival in NSCLC

ESMO 2018: Pembrolizumab Extends Quality Survival in NSCLC

A new analysis of the KEYNOTE 024 and KEYNOTE 010 trials found that patients who receive pembrolizumab not only live longer, they...
Immunotherapy with Pembrolizumab Improves Head/Neck Cancer Survival

Immunotherapy with Pembrolizumab Improves Head/Neck Cancer Survival

According to a breaking presentation from ESMO Congress 2018 in Munich, immunotherapy with pembrolizumab demonstrated increased survival in patients with recurred or metastasized...
Neoadjuvant Erlotinib Improves PFS in mutated-NSCLC

Neoadjuvant Erlotinib Improves PFS in mutated-NSCLC

A presentation at ESMO Congress 2018 in Munich determined that neoadjuvant erlotinib benefited a subset of patients with early-stage EGFR-mutated non-small cell lung cancer...

Loading...